Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.
about
Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.A feed forward loop enforces YAP/TAZ signaling during tumorigenesisThe potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
P2860
Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Dual Targeting of CDK4 and ARK ...... vity against Multiple Myeloma.
@en
type
label
Dual Targeting of CDK4 and ARK ...... vity against Multiple Myeloma.
@en
prefLabel
Dual Targeting of CDK4 and ARK ...... vity against Multiple Myeloma.
@en
P2093
P2860
P1433
P1476
Dual Targeting of CDK4 and ARK ...... vity against Multiple Myeloma.
@en
P2093
Ajai Chari
Deepak Perumal
E Premkumar Reddy
Hearn Jay Cho
Joshua Brody
M V Ramana Reddy
Pei-Yu Kuo
Sai Krishna Athaluri Divakar
Samir Parekh
Sundar Jagannath
P2860
P304
P356
10.1158/0008-5472.CAN-15-2934
P407
P577
2016-02-12T00:00:00Z